Investor Presentaiton
R&D investor presentation
Once-weekly insulin icodec appeared to have a similar safety
profile to once-daily insulin glargine U100 in the phase 2 trial
No statistically significant difference in the number of
hypoglycaemic events between icodec and glargine U100
11
Insulin icodec appeared to have a safe profile
Hyoglycemia during
Icodec
Glargine U100
Rates of nocturnal events were low
the on-treatment
N
E
E
period
(%)
(R)
(%)
(R)
Hypoglycaemia alert
67
368
46
value (Level 1)
(53.6)
(508.89)
(37.7)
148
(210.80)
No cardiovascular events
Severe (Level 3) or
20
clinically significant
(16.0)
38
(52.55)
12
(9.8)
32
No new safety issues identified
related to insulin icodec
(45.58)
(Level 2) hypoglycaemia
Severe hypoglycaemia
(Level 3)
1
1
0
(0.8)
(1.38)
N: number of patients with one or or more events; E: number of events; %: percentage of patients with one or more events; R: rate (number of events divided by patient years of exposure
multiplied by 100)
novo nordiskView entire presentation